Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Bokf Na

Bokf Na reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 12.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 24,548 shares of the biopharmaceutical company’s stock after selling 3,636 shares during the quarter. Bokf Na’s holdings in Catalyst Pharmaceuticals were worth $538,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Castlekeep Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth $37,494,000. Bank of America Corp DE boosted its holdings in Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after acquiring an additional 913,843 shares during the period. Ameriprise Financial Inc. grew its position in Catalyst Pharmaceuticals by 1.9% in the 4th quarter. Ameriprise Financial Inc. now owns 282,834 shares of the biopharmaceutical company’s stock valued at $5,903,000 after acquiring an additional 5,177 shares in the last quarter. Algert Global LLC increased its stake in Catalyst Pharmaceuticals by 185.2% during the fourth quarter. Algert Global LLC now owns 47,920 shares of the biopharmaceutical company’s stock worth $1,000,000 after purchasing an additional 31,115 shares during the period. Finally, PDT Partners LLC lifted its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $23.37 on Friday. The firm’s fifty day moving average price is $22.99 and its 200 day moving average price is $22.39. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 19.81, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Finally, Stephens reiterated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.